Bristol Myers Squibb Company $BMY Shares Sold by Keybank National Association OH

Keybank National Association OH lessened its position in shares of Bristol Myers Squibb Company (NYSE:BMY) by 1.6% in the third quarter, Holdings Channel.com reports. The firm owned 492,372 shares of the biopharmaceutical company’s stock after selling 8,259 shares during the period. Keybank National Association OH’s holdings in Bristol Myers Squibb were worth $30,724,000 as of its most recent SEC filing.

A number of other large investors have also recently added to or reduced their stakes in the company. Pinion Investment Advisors LLC boosted its position in shares of Bristol Myers Squibb by 3.8% during the third quarter. Pinion Investment Advisors LLC now owns 4,316 shares of the biopharmaceutical company’s stock worth $269,000 after buying an additional 158 shares during the period. Altura Wealth Advisors Inc. grew its holdings in shares of Bristol Myers Squibb by 1.2% during the third quarter. Altura Wealth Advisors Inc. now owns 13,717 shares of the biopharmaceutical company’s stock worth $856,000 after buying an additional 161 shares in the last quarter. Capital City Trust Co. FL raised its position in Bristol Myers Squibb by 0.7% in the 3rd quarter. Capital City Trust Co. FL now owns 23,321 shares of the biopharmaceutical company’s stock valued at $1,455,000 after buying an additional 167 shares during the last quarter. Eagle Bay Advisors LLC raised its position in Bristol Myers Squibb by 2.6% in the 3rd quarter. Eagle Bay Advisors LLC now owns 6,536 shares of the biopharmaceutical company’s stock valued at $408,000 after buying an additional 168 shares during the last quarter. Finally, Blue Bell Private Wealth Management LLC raised its position in Bristol Myers Squibb by 21.1% in the 3rd quarter. Blue Bell Private Wealth Management LLC now owns 969 shares of the biopharmaceutical company’s stock valued at $60,000 after buying an additional 169 shares during the last quarter. Institutional investors own 76.41% of the company’s stock.

Insiders Place Their Bets

In other Bristol Myers Squibb news, SVP Phil M. Holzer sold 500 shares of the stock in a transaction on Tuesday, August 25th. The shares were sold at an average price of $67.50, for a total value of $33,750.00. Following the completion of the sale, the senior vice president owned 16,862 shares in the company, valued at $1,138,185. This trade represents a 2.88% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Julia Haller sold 3,800 shares of Bristol Myers Squibb stock in a transaction dated Thursday, November 5th. The shares were sold at an average price of $63.31, for a total transaction of $240,578.00. Following the completion of the transaction, the director directly owned 30,279 shares of the company’s stock, valued at approximately $1,916,963.49. This trade represents a 11.15% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 0.05% of the company’s stock.

Bristol Myers Squibb Stock Performance

BMY opened at $62.91 on Thursday. The business’s 50-day simple moving average is $62.09 and its 200 day simple moving average is $60.23. Bristol Myers Squibb Company has a 52-week low of $45.26 and a 52-week high of $68.64. The company has a debt-to-equity ratio of 1.79, a quick ratio of 1.44 and a current ratio of 1.59. The firm has a market capitalization of $128.59 billion, a PE ratio of 10.08, a PEG ratio of 0.32 and a beta of 0.20.

Bristol Myers Squibb (NYSE:BMY) last posted its quarterly earnings results on Thursday, October 29th. The biopharmaceutical company reported $1.35 earnings per share for the quarter, beating analysts’ consensus estimates of $1.10 by $0.25. Bristol Myers Squibb had a return on equity of 60.48% and a net margin of 18.47%. The firm had revenue of $13.07 billion during the quarter, compared to the consensus estimate of $12.72 billion. During the same period last year, the company earned $1.63 earnings per share. The business’s revenue was up 6.9% compared to the same quarter last year. As a group, sell-side analysts expect that Bristol Myers Squibb Company will post 6.45 earnings per share for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Monday, November 2nd. Shareholders of record on Friday, October 2nd were given a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a yield of 4.0%. The ex-dividend date of this dividend was Friday, October 2nd. Bristol Myers Squibb’s dividend payout ratio is 55.88%.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on BMY. Rothschild & Co Redburn upped their price target on Bristol Myers Squibb from $51.00 to $53.00 and gave the stock a “neutral” rating in a research report on Thursday, October 8th. BMO Capital Markets reaffirmed a “market perform” rating on shares of Bristol Myers Squibb in a research note on Monday, July 27th. JPMorgan Chase & Co. lifted their price objective on shares of Bristol Myers Squibb from $67.00 to $73.00 and gave the company an “overweight” rating in a report on Friday, July 31st. Weiss Ratings raised shares of Bristol Myers Squibb from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Tuesday, August 18th. Finally, Zacks Research lowered shares of Bristol Myers Squibb from a “strong-buy” rating to a “hold” rating in a research report on Thursday, October 22nd. Two analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, sixteen have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Bristol Myers Squibb currently has a consensus rating of “Hold” and a consensus target price of $65.46.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company that discovers, develops, manufactures and markets medicines. Its research and commercial activities focus on serious diseases, particularly cancer, blood disorders, immune-mediated conditions and cardiovascular disease. The company’s medicines include Opdivo and Yervoy for cancer, Eliquis for preventing and treating blood clots, and Orencia for certain autoimmune conditions. Its portfolio also includes treatments for hematologic diseases and other serious illnesses.